Silencing of microRNA-155 in mice during acute inflammatory response leads to derepression of c/ebp Beta and down-regulation of G-CSF by Worm, Jesper et al.
5784–5792 Nucleic Acids Research, 2009, Vol. 37, No. 17 Published online 13 July 2009
doi:10.1093/nar/gkp577
Silencing of microRNA-155 in mice during acute
inflammatory response leads to derepression of
c/ebp Beta and down-regulation of G-CSF
Jesper Worm
1, Jan Stenvang
1,2, Andreas Petri
1, Klaus Stensgaard Frederiksen
3,
Susanna Obad
1, Joacim Elme ´n
1, Maj Hedtja ¨rn
1, Ellen Marie Straarup
1,
Jens Bo Hansen
1 and Sakari Kauppinen
1,2,*
1Santaris Pharma, Kogle Alle ´ 6, DK-2970 Hørsholm,
2Wilhelm Johannsen Centre for Functional Genome
Research, Department of Cellular and Molecular Medicine, University of Copenhagen, Blegdamsvej 3, DK-2200
Copenhagen N and
3Novo Nordisk A/S, Novo Alle ´ 3, DK-2880 Bagsværd, Denmark
Received December 3, 2008; Revised June 4, 2009; Accepted June 22, 2009
ABSTRACT
microRNA-155 (miR-155) has been implicated as a
central regulator of the immune system, but its func-
tion during acute inflammatory responses is still
poorly understood. Here we show that exposure of
cultured macrophages and mice to lipopolysacchar-
ide (LPS) leads to up-regulation of miR-155 and that
the transcription factor c/ebp Beta is a direct target
of miR-155. Interestingly, expression profiling of
LPS-stimulated macrophages combined with over-
expression and silencing of miR-155 in murine
macrophages and human monocytic cells uncov-
ered marked changes in the expression of granulo-
cyte colony-stimulating factor (G-CSF), a central
regulator of granulopoiesis during inflammatory
responses. Consistent with these data, we show
that silencing of miR-155 in LPS-treated mice by
systemically administered LNA-antimiR results
in derepression of the c/ebp Beta isoforms and
down-regulation of G-CSF expression in mouse
splenocytes. Finally, we report for the first time on
miR-155 silencing in vivo in a mouse inflammation
model, which underscores the potential of miR-155
antagonists in the development of novel therapeu-
tics for treatment of chronic inflammatory diseases.
INTRODUCTION
MicroRNAs (miRNAs) are an abundant class of small
endogenous noncoding RNAs that post-transcriptionally
regulate gene expression by base-pairing to imperfect
complementary target sites in the 30 UTR of their target
mRNAs, thereby mediating mRNA cleavage or transla-
tional repression (1). miRNAs have emerged as key reg-
ulators of diverse biological processes, including
diﬀerentiation of hematopoeitic cells (2,3) and activation
of the innate immune response (4,5). miR-155 is expressed
in activated mature B and T lymphocytes (6,7) and in
activated monocytes (8,9), while studies using miR-155
knockout mice have directly linked this miRNA to the
functions of the immune system (6,7). In addition, miR-
155 has been shown to regulate the production of cyto-
kines, chemokines and transcription factors (6,7) and to be
induced by endotoxins, such as bacterial lipopolysacchar-
ide (LPS) (8–10). Recently, miR-155 was shown to direct
the generation of immunoglobulin class-switched plasma
cells (11) and to directly regulate the AID enzyme (activa-
tion-induced cytidine deaminase), which is responsible for
the generation of functionally diverse antibody repertoires
(12,13). Altogether, these observations strongly imply
miR-155 as a central regulator of the immune system.
With the goal of gaining further insights into the bio-
logical function of miR-155 during acute inﬂammatory
response, we have undertaken stimulation of cultured
murine macrophage Raw264.7 and human THP-1 mono-
cytic cells as well as treatment of mice by bacterial LPS.
Previous studies have shown that the transcription factor
CCAAT/enhancer binding protein Beta (c/ebp Beta) is
induced in monocytes and macrophages by LPS (14) and
that c/ebp Beta is involved in the regulation of proinﬂam-
matory cytokines as well as other genes associated with
macrophage activation and the acute phase response
(15,16). We report here that LPS treatment induces
miR-155 expression in cultured mouse macrophages and
in mouse splenocytes in vivo and that silencing of miR-155
leads to derepression of its direct target c/ebp Beta in vitro
and in vivo. Additionally, we ﬁnd that antagonism of
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of granulopoiesis, produced by activated macrophages
during acute inﬂammatory responses. G-CSF belongs
to the class of colony-stimulating factors (CSFs), which
comprise granulocyte/macrophage CSF (GM-CSF),
macrophage CSF (M-CSF) and granulocyte CSF
(G-CSF). During progression of inﬂammatory diseases
the CSFs have been suggested to constitute a pro-inﬂam-
matory CSF network, which at the site of inﬂammation
involves CSF-mediated communication between stimu-
lated macrophages and neighboring cell types (17). This
positive-feedback loop model predicts that CSF blocking
agents could be eﬃcient anti-inﬂammatory drugs. Indeed,
data from animal models indicate that depletion of CSFs
has therapeutic value in inﬂammatory and autoimmune
diseases. While early-phase clinical trials targeting GM-
CSF and M-CSF have been initiated, no clinical trials
on depletion of G-CSF have yet been reported (18).
Our data show for the ﬁrst time that c/ebp Beta is regu-
lated by miR-155 in vivo in mouse splenocytes during
inﬂammatory responses. Moreover, we report that miR-
155 mediates regulation of G-CSF expression, thereby
underscoring the role of miR-155 in ﬁne-tuning important
regulatory networks during inﬂammation.
MATERIALS AND METHODS
Design and synthesis of LNA oligonucleotides
The LNA-antimiR oligonucleotides were synthesized as
unconjugated and fully phosphorothiolated oligonucleo-
tides. The perfectly matching LNA-antimiR oligonucleo-
tide 50-TcAcAATtaG
mCAtTA-30 was complementary to
nucleotides 2–16 in the mature murine miR-155 sequence
and 50-TcAcGATtaG
mCAtTA-30 was complementary to
nucleotides 2–16 in the mature human miR-155 sequence.
The mismatch LNA control oligonucleotide was synthe-
sized with the following sequence: 50-TcAa
mCATt
aGA
mCtTA-30 (uppercase: LNA; lowercase: DNA;
mC
denotes LNA methylcytosine).
Cell culture
Raw264.7 cells were grown in Dulbecco’s modiﬁed Eagle’s
medium (DMEM) (Invitrogen) supplemented with 10%
FBS, 4mM Glutamax I and 25mg/ml Gentamicin
(Invitrogen). Lipopolysaccharide (LPS) was purchased
from Sigma and activation of Raw264.7 cells was induced
by treating cells with 1, 10 or 100ng/ml LPS for indicated
time periods. THP-1 cells were grown in RPMI-1640
(Invitrogen) supplemented with 10% FBS, 4mM
Glutamax I and 25mg/ml Gentamicin (Invitrogen).
Raw264.7 and THP-1 cells were transfected with the
Lipofectamine 2000 transfection reagent according to the
manufacturer’s protocol (Invitrogen) and the LNA-
antimiR oligonucleotides were used at a ﬁnal concentra-
tion of 5nM unless otherwise stated. Human miR-155
precursor (pre-miR-155, Ambion) was cotransfected at
a ﬁnal concentration of 5nM. HeLa cells were cultivated
in Eagles MEM (Invitrogen) with 10% FBS, 2mM
Glutamax I, non-essential amino acids and 25mg/ml
Gentamicin (Invitrogen). HeLa cells were co-transfected
with human pre-miR-155 (Ambion) at a ﬁnal concen-
tration of 50nM and 0.1mg luciferase reporter con-
struct using Lipofectamine 2000. The transfections
and luciferase activity measurements were carried out
according to the manufacturer’s instructions (Invitrogen
Lipofectamine 2000/Promega Dual-luciferase kit).
Relative luciferase activity levels were expressed as
Renilla/ﬁreﬂy luciferase ratios.
Plasmids
The perfect match target sites for the human and the
murine miR-155, respectively, were cloned downstream
of the Renilla luciferase gene (XhoI/NotI sites) in the
psiCHECK2 vector (Promega) using 50 phosphorylated
oligos: murine miR-155 forward 50-tcgagcccctatcacaattag
cattaagc-30, and reverse 50-ggccgcttaatgctaattgtgatagg
ggc-30; human miR-155 forward 50-tcgagcccctatcacgattag
cattaagc-30 and reverse 50-ggccgcttaatgctaatcgtgatagggg-30.
The 30 UTR of human c/ebp Beta was cloned downstream
of the Renilla luciferase gene (XhoI/NotI sites) in the
psiCHECK2 vector. PCR primers used for ampliﬁcation
of the human c/ebp Beta 30 UTR (basepairs 1328–1837
accession no. NM_005194) were: forward 50-aaaaaactcga
gaaaactttggcactggggca-30 (incl. a XhoI site), reverse 50-aaa
aaagcggccgcggctttgtaaccattctcaaa-30 (incl. a NotI site).
The miR-155 target site in the c/ebp Beta 30 UTR was
mutated by deleting the 8nt miR-155 seed match sequence
(AGCAUUAA at nucleotide positions 554–561 in the
c/ebp Beta 30 UTR) using the QuikChange Site-Directed
Mutagenesis kit according to manufacturer’s instructions
(Stratagene). The pCDNA3.1 expression construct for
the truncated rat c/ebp Beta isoform LIP (amino acids
153–297) was kindly provided by Dr. M.A. Chidgey and
has been described elsewhere (19).
Western blot analysis
Raw264.7 and spleen proteins were extracted using RIPA
lysis buﬀer (50mM Tris–HCl pH 7.4, 150mM NaCl,
1mM EDTA, 1% Triton X-100, 0.1% SDS, 1% sodium
deoxycholate) and electrophoresed on NuPAGE Bis Tris
4–12% gels (Invitrogen) using 100mg protein per sample.
The proteins were transferred to a nitrocellulose mem-
brane using iBlot (Invitrogen) according to manufac-
turer’s instructions. ECL advanced western kit (GE
Healthcare Life Sciences) was used for blocking, antibody
dilution and detection according to the manufacturer.
A primary monoclonal mouse-anti-c/ebp Beta antibody
(SC-7962, Santa Cruz Biotechnology), a primary
rabbit-anti-PU.1 (#2258, Cell signaling Technology),
a primary mouse-anti- Tubulin-alpha Ab-2 (MS-581-P,
Neomarkers) and HRP-conjugated secondary rabbit
anti-mouse (P0447, DAKO) or swine anti-rabbit antibo-
dies (P0399, DAKO) were used according to the manufac-
turer’s instructions.
Quantitative RT-PCR
The dissected mice spleens were immediately stored
in RNA later (Ambion). Total RNA from spleens or
Raw264.7 cells was extracted with Trizol reagent accord-
ing to the manufacturer’s instructions (Invitrogen), except
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nol and not mixed. The miR-155 levels were quantiﬁed
using the mirVana real-time RT-PCR detection kit
(Ambion) following the manufacturer’s instructions,
except that 200ng total RNA was used in the reverse tran-
scription (RT) reaction. A 2-fold total RNA dilution series
from LPS-treated mouse spleen RNA or LPS-treated
Raw264.7 RNA served as standard to ensure a linear
range (Ct versus relative copy number) of the ampliﬁca-
tion. The RT reaction was diluted ten times in water and
10ml aliquots were subsequently used for RT-PCR ampli-
ﬁcation according to the manufacturer’s instructions
(Ambion). mRNA quantiﬁcation of selected genes
was done using standard TaqMan assays (Applied
Biosystems). The reverse transcription reaction was car-
ried out with random decamers, 0.5mg total RNA and the
M-MLV RT enzyme from Ambion according to protocol.
First-strand cDNA was subsequently diluted 10 times in
nuclease-free water before addition to the RT-PCR reac-
tion mixture. The Applied Biosystems 7500 Real-Time
PCR instrument was used for ampliﬁcation, except that
the Applied Biosystems 7900 Real-Time PCR instrument
was used for ampliﬁcation of 96 transcripts included on
the low density mouse immune array from Applied
Biosystems.
In vivo experiments
C57BL/6J female mice (Taconic Europe A/S) kept on a
regular chow diet (Altromin no 1324, Brogaarden) and
with an average body weight of  20g ( 2g) at the start
of the experiment were used in all studies. The experiments
were carried out following the Danish Committee for
Animal Experiments guidelines. The animal cages were
illuminated to give a 12-h light/dark cycle. The tempera-
ture was 218C   28C and relative humidity 55 10%.
The LNA compounds were formulated in physiological
saline (0.9% NaCl) to a ﬁnal concentration allowing the
mice to receive a tail vein injection volume of 10ml/kg.
The animals were dosed for three consecutive days with
LNA-antimiR, LNA control or saline (vehicle control),
receiving daily doses of 25mg/kg and sacriﬁced 24h
after last dose. Saline-formulated bacterial LPS was admi-
nistered by intraperitoneal injections at 0.5mg/kg and the
mice were sacriﬁced either 2 or 24h post-LPS treatment.
Immediately after sacriﬁcing the animals, spleen samples
were dissected.
Isolation of B cells and monocytic/macrophage
cell fractions from mice splenocytes
C57BL/6J female mice (Taconic Europe A/S) were
injected intravenously with a FAM-labeled LNA con-
trol for three consecutive days, receiving daily doses
of 25mg/kg and the animals were sacriﬁced 24h after
last dose. Spleens were surgically removed and positive
selection of monocytes/macrophages was carried out by
MACS Cell separation systems (Miltenyi Biotech)
using magnetic beads conjugated with CD11b antibodies
and the MACS Cell separation columns according
to the manufacturer’s instructions (Miltenyi Biotec). B
cells were isolated using magnetic beads conjugated with
CD19 antibodies (Miltenyi Biotec). PE-conjugated CD11b
and CD19 antibodies were added to isolated fractions
to verify the identity of the isolated cells by FACS analy-
sis. Fixed isolated cells were DAPI stained and trans-
ferred to microscope slides. Cellular uptake of the
FAM-labeled LNA oligonucleotide was investigated by
confocal microscopy.
RESULTS
LPS-mediated induction of miR-155 in cultured mouse
Raw264.7 macrophages
Since miR-155 has previously been shown to be upregu-
lated during macrophage activation (8–10) we ﬁrst inves-
tigated the expression of miR-155 in murine Raw264.7
macrophage cells upon LPS stimulation. Treatment of
cultured mouse macrophages with LPS showed dose-
dependent induction of miR-155 with more than 10-fold
increase in miR-155 expression levels at a concentration of
100ng/ml LPS after 18h (Figure 1A). Consistent with
these data, a luciferase reporter construct harbouring a
perfect match miR-155 target site in the 30 UTR of the
Renilla luciferase gene showed a concentration-dependent
repression of the luciferase reporter, which correlated with
the increased expression of miR-155 in LPS-treated mouse
Raw264.7 macrophages (Figure 1B). We have recently
reported on eﬀective miRNA silencing using complemen-
tary LNA-antimiR oligonucleotides in combination with
transcriptome analysis as a useful approach to dissect the
biological roles of individual miRNAs in vitro and in vivo
(20,21). Hence, to enable further studies on miR-155 tar-
gets and miR-155 associated gene networks, we designed
an LNA-antimiR complementary to mature miR-155
alongside an LNA control oligonucleotide having four
mismatches in the miR-155 recognition sequence. The
LNA-antimiR-155 showed concentration-dependent
silencing of miR-155 in LPS-treated mouse Raw264.7
macrophages as shown by eﬃcient derepression of the
miR-155 sensor, whereas the LNA control oligonucleo-
tide had no eﬀect on the luciferase reporter activity at
the same concentrations (Figure 1C). Since the LNA-
antimiR resulted in potent and speciﬁc antagonism of
miR-155 in cultured Raw264.7 cells at 5-nM concentra-
tion, we chose these experimental conditions for further
studies in mouse macrophages.
Translational repression of c/ebp Beta isoforms by miR-155
LPS stimulation of cultured mouse Raw264.7 cells leads to
an inﬂammatory response in which miR-155 and more
than 700 genes are up-regulated (22), including the tran-
scription factor c/ebp Beta gene (14). Interestingly, the
c/ebp Beta transcript is predicted by several computer
algorithms (PicTar, miRanda, TargetScan) to be a miR-
155 target due to the presence of a miR-155 target site in
its 30 UTR, which is highly conserved among ﬁve verte-
brate species (Figure 2A). Indeed, we found that a lucifer-
ase reporter harbouring the c/ebp Beta 30 UTR showed
signiﬁcant (P<0.001, Student’s t-test, two-sided) miR-
155-dependent repression relative to a control reporter
plasmid (Figure 2B), implying that c/ebp Beta is a direct
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reports (23,24). Deletion of the highly conserved miR-155
seed match site (positions 554–561; AGCAUUAA) in the
c/ebp Beta 30 UTR abrogated the eﬀect of miR-155. Com-
bined these data support the notion that c/ebp Beta is
post-transcriptionally regulated by miR-155 (Figure 2B
and Supplementary Figure 1).
The c/ebp Beta transcript encodes three isoforms,
designated as LAP , LAP and LIP, that are generated
by diﬀerential translational initiation (Figure 2A). The
short LIP form lacks the transactivation domain (TAD),
but is still capable of binding to DNA and forms homo- or
heterodimers through the basic region leucine zipper
(bZIP) domain and therefore behaves as a dominant nega-
tive. The expression of the three isoforms is regulated in
a complex manner, and even diﬀerential activation of the
c/ebp Beta isoforms upon LPS stimulation has been
reported (25).
To assess miR-155-mediated regulation of the various
c/ebp Beta isoforms, we investigated protein extracts from
murine macrophages by Western blot analyses using a
C-terminal speciﬁc c/ebp Beta antibody that recognizes
all three isoforms. Transient transfection of a precursor
miR-155 (pre-miR-155) at 5-nM concentration into
mouse Raw264.7 macrophages resulted in signiﬁcant
repression of the c/ebp Beta isoforms LIP and LAP,
whereas concomitant transfection with equimolar LNA-
antimiR into the cells eﬀectively antagonized the miR-
155-mediated c/ebp Beta repression compared to the
LNA control transfected cells (Figure 2C). We also
observed repression of another direct miR-155 target,
the Ets family transcription factor Pu.1 in Raw264.7
cells (Figure 2C) (11), implying that both c/ebp Beta and
Pu.1 are targeted by miR-155 in the Raw264.7 macro-
phage model system. We obtained similar results with
undiﬀerentiated human monocytic THP-1 cells, in which
transfection with pre-miR-155 resulted in repression of the
c/ebp Beta isoforms (Figure 2D). Taken together, our data
suggest that the levels of individual c/ebp Beta isoforms
are regulated by ectopically expressed miR-155.
Figure 1. LPS-mediated induction of miR-155 in cultured mouse Raw264.7 macrophages. (A) Quantitative RT-PCR analysis of miR-155 expression
in Raw264.7 cells stimulated with LPS for 18h at the indicated concentrations. Values represent mean   SD (n=3). (B) Assessment of luciferase
reporter activity in Raw264.7 cells transfected with either the Renilla/ﬁreﬂy luciferase psiCHECK2 control or psiCHECK2 harbouring the miR-155
perfect match target site in the 30 UTR of the Renilla luciferase transcript (miR-155 sensor). After transfection, the Raw264.7 cells were stimulated
with the indicated concentrations of LPS for 18h. Values represent mean   SD (n=3). (C) Assessment of luciferase reporter activity in Raw264.7
cells cotransfected with LNA-antimiR or LNA control in combination with either the Renilla/ﬁreﬂy luciferase psiCHECK2 control (data not shown)
or the miR-155 sensor. Raw264.7 cells were stimulated with 100ng/ml LPS for 18h. Values represent mean   SD (n=3).
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LPS stimulation
We next investigated the eﬀect of endogenous miR-155 on
c/ebp Beta expression during LPS stimulation by treating
mouse macrophage Raw264.7 cells with LNA-antimiR
followed by exposure of the cells to LPS. Western blot
analysis using the C-terminal speciﬁc c/ebp Beta antibody
showed that the levels of both the LAP and LIP isoforms
of c/ebp Beta were increased after treatment with LPS,
inaccordance with aprevious report (14) (Figure 3). Trans-
fection of the LNA-antimiR (5nM) into the Raw264.7
macrophagesprior to LPSstimulation resulted inderepres-
sion of the c/ebp Beta isoforms (Figure 3), which
thereby provides additional evidence that the levels of indi-
vidual c/ebp Beta isoforms are regulated by endogenous
miR-155 in mouse macrophages during LPS stimulation.
miR-155 regulates c/ebp Beta in the splenocytes of
LPS-treated mice
The expression of c/ebp Beta is induced during macro-
phage activation, whereas Pu.1 is expressed both in resting
B cells and macrophages and in the spleen germinal center
B cells (14,26). Since spleen contains populations of mono-
cytes and macrophages together with B and T cells, we
investigated miR-155-mediated regulation of c/ebp Beta
in the splenocytes of LPS-treated mice in combination
with LNA-antimiR based miR-155 silencing. We ﬁrst
asked whether these cells could be targeted by systemically
administered LNA oligonucleotides in vivo by isolating B
cells and monocytic cell populations from murine spleen
after intravenous dosing with a 6-carboxyﬂuorescein
(FAM)-labeled LNA oligonucleotide. Confocal micros-
copy of the murine B cells and monocytes/macrophages
showed that the FAM-labeled LNA was readily taken up
by these cells, indicating that miR-155 could be targeted in
both cell types by an LNA-antimiR compound
(Figure 4A). Intraperitoneal administration of LPS signif-
icantly induced the expression of miR-155 in splenocytes
2h post-treatment, thereby corroborating our results
obtained with LPS-stimulated murine macrophages
(Figure 4B). The splenocytes of untreated mice showed
low levels of c/ebp Beta proteins, whereas the levels
of both the LAP and LIP isoform of c/ebp Beta were
B A
Hsa UUUUCCGUUUCA--AGCAUUAA-------GAACACUUUUAAUAAAC
Mmu UUUUCCGUUUCG--AGCAUUAA--AGUGAAGACA-UUUUAAUAAAC 
Rno UUUUCCGUUUCG--AGCAUUAA--AGUGAAGACA-UUUUAAUAAAC
Cfa UUUUCCGUUUCA--AGCAUUAA-------GAACACUUUUAAUAAAC
Gga UGCUACAUUUGA--AGCAUUAA------UGAACGAUUUUAAUAAAC 
AAAAA  3’ 5’
hsa miR-155   3’-GGGGAUAGUGCUAAUCGUAAUU-5’
1 605
554 561
ATG ATG ATG
*LAP LAP LIP
TAD bZIP
*LAP
LAP
LIP
Tubulin
Pu.1
Pre-miR-155 
C
LAP
LIP
100
75
50
25
0
100
75
50
25
0
R
e
l
a
t
i
v
e
e
x
p
r
e
s
s
i
o
n
R
e
l
a
t
i
v
e
e
x
p
r
e
s
s
i
o
n
Pre-miR-155
Raw264.7
HeLa
LNA-antimiR LNA control LNA-antimiR
Tubulin
Pre-miR-155
LNA-antimiR LNA control
Pu.1
*LAP
LAP
LIP
THP-1
D
–+–+–+ –+–+–+
–+–+
Pre-miR-155
R
e
l
a
t
i
v
e
 
l
u
c
i
f
e
r
a
s
e
 
a
c
t
i
v
i
t
y
 
(
%
)
miR-155
Sensor
c/ebp Beta
3′UTR
c/ebp Beta
3′UTR Mut
Control
–
0
20
40
60
80
100
120
+– +– +– +
***
LNA control
Figure 2. Translational repression of c/ebp Beta isoforms by miR-155. (A) Schematic overview of the c/ebp Beta transcript. The miR-155 target site
is indicated in the 30 UTR with the 8-nt seed match boxed. TAD, transactivation domain; bZIP, basic region leucine zipper domain; ATG,
translational start site; LAP, liver-enriched transcriptional activation protein; LIP, liver-enriched transcriptional inhibitory protein.
(B) Assessment of luciferase reporter activity in HeLa cells cotransfected with pre-miR-155 in combination with either the Renilla/ﬁreﬂy luciferase
psiCHECK2 control, the psiCHECK2 luciferase construct (miR-155 sensor) harbouring the miR-155 perfect match target site, the psiCHECK2
construct harbouring the c/ebp Beta 30 UTR, or the psiCHECK2c/ebp Beta 30 UTR Mut construct harbouring a mutated miR-155 target site. Values
represent mean   SD (n=3). The pre-miR-155 signiﬁcantly represses the luciferase activity of the c/ebp Beta 30 UTR sensor construct (    indicates
P<0.001). (C) Western blot analysis of c/ebp Beta LAP , LAP and LIP isoforms and Pu.1 in Raw264.7 cell lysates. Protein extracts from Raw264.7
cells cotransfected with 5nM pre-miR-155 in combination with either LNA control (5nM) or LNA-antimiR (5nM) were subjected to western blot
analysis. (Right) Quantiﬁcation of the LIP and LAP protein bands shown on the western blot. Values represent mean   SD (n=3). (D) Western
blot analysis of the c/ebp Beta LAP and LIP isoforms and Pu.1 protein in THP-1 cell lysates. Protein extracts from THP-1 cells cotransfected with
pre-miR-155 (5nM) in combination with either LNA control (5nM) or LNA-antimiR (5nM) were subjected to western blot analysis. Data are
representative of three independent experiments.
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(Figure 4C), in accordance with a previous report (14).
Systemic administration of the LNA-antimiR in LPS-
treated mice eﬀectively antagonized miR-155 compared
to the vehicle and LNA-mismatch-control-treated mice,
respectively (Figure 4B). This resulted in signiﬁcant dere-
pression of both the LAP and LIP isoforms in comparison
to the vehicle-treated control mice (Figure 4C), which is
consistent with the notion that miR-155 negatively regu-
lates c/ebp Beta proteins in vivo in mouse splenocytes
during acute inﬂammatory response.
miR-155 mediates regulation of G-CSF
Recent studies using knockout mice have implicated
miR-155 in the regulation of cytokines and chemokines
in T and B cells (6,7). Thus, to identify immune response
genes whose expression could be modulated by miR-155 in
activated macrophages, we carried out expression proﬁl-
ing of RNA samples extracted from LPS-stimulated
mouse Raw264.7 cells using mouse immune real-time
RT-PCR arrays (Supplementary table S1). To establish a
link between miR-155 and the expression of immune
response genes, the LPS-stimulated Raw264.7 cells were
transfected with either LNA-antimiR-155 or LNA con-
trol. Interestingly, among the immune response genes
induced by LPS treatment, expression of the Csf3 gene
encoding G-CSF was signiﬁcantly down-regulated in
LNA-antimiR-treated cells compared to the untreated
and LNA controls (P=0.014 and P=0.008, respectively,
Student’s t-test, two-sided), implying that the regulation of
G-CSF expression is mediated by miR-155 (Figure 5A,
Supplementary table S1).
To validate this conclusion we assessed the eﬀect of
miR-155 on G-CSF expression in human monocytic
THP-1 cells. Transient transfection of pre-miR-155
into LPS-stimulated THP-1 cells resulted in signiﬁcant
up-regulation of the G-CSF mRNA (P<0.01, Student’s
t-test, two-sided), that reverted to control levels upon
antagonism of miR-155 by LNA-antimiR (Figure 5B).
Consistent with our data on mouse macrophages and
human monocytes, we observed that the G-CSF mRNA
was signiﬁcantly down-regulated in the splenocytes
of miR-155 antagonized LPS-treated mice (P=0.0007
and P=0.02, Student’s t-test, two-sided) compared to
saline and LNA-control-treated animals, respectively
(Figure 5C). The miR-155-mediated eﬀect on G-CSF
mRNA in mouse splenocytes was robust as it was
observed in three independent in vivo experiments (data
not shown). Considered together, our data suggest that
miR-155 mediates regulation of G-CSF expression
during acute inﬂammatory response.
DISCUSSION
Inﬂammatory responses are initiated by monocytes that
upon recognition of pathogens diﬀerentiate into macro-
phages, which then become activated to produce cytokines
and chemokines. These inﬂammatory mediators help
recruit eﬀector cells to the site of infection and induce
endothelial cell activation to increase vascular permeabil-
ity (22). Several transcription factors are important for
diﬀerentiation and activation of myeloid lineages, includ-
ing the CCAAT/enhancer binding protein Beta (c/ebp
Beta), which has been implicated in the regulation of
proinﬂammatory cytokines during macrophage activation
and the acute phase response (15,16). In this study, we
show that c/ebp Beta is a bona ﬁde target of miR-155
and that LPS treatment of murine macrophages strongly
induces miR-155 expression, leading to translational
repression of c/ebp Beta. Our observations are in good
agreement with recent reports, showing that ectopically
expressed miR-155 can target c/ebp Beta in vitro (9,24).
Moreover we report here that functional inhibition
of endogenous miR-155 in vitro leads to derepression of
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Figure 3. Regulation of c/ebp Beta isoforms by endogenous miR-155 in Raw264.7 cells during LPS stimulation. Western blot analysis of c/ebp Beta
LAP , LAP and LIP isoforms in Raw264.7 cell lysates. Protein extracts from Raw264.7 cells either mock (control) or LNA-antimiR (5nM)
transfected before treatment with 100ng/ml LPS for 18h were subjected to western blot analysis. (Right) Quantiﬁcation of the LIP, LAP and
LAP  protein bands shown on the western blot. Values represent mean   SD (n=3) (    indicates P<0.01;   indicates P<0.05). Data represent
three independent experiments.
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Figure 4. miR-155 regulates c/ebp Beta in the splenocytes of LPS-treated mice. (A) Fluorescence-microscopy analysis of LNA oligonucleotide uptake
in mouse splenocytes sorted in either B-cell (CD19) or monocytic (CD11b) cell fractions. Mice were dosed intravenously with 25mg/kg FAM-labeled
LNA oligonucleotide for three consecutive days, and spleens were dissected the day after last dose. (B) Quantitative RT-PCR analysis of miR-155
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Spleen samples were dissected 2h after intraperitoneal injection of 0.5mg/kg LPS. Values represent mean   SD (n=5). The LNA-antimiR com-
pound eﬀectively antagonizes miR-155 expression in LPS-treated mice compared to saline treated controls (    indicates P<0.001). (C) Western blot
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Figure 5. Antagonism of miR-155 leads to down-regulation of the granulocyte colony-stimulating factor (G-CSF). (A) Quantitative RT-PCR analysis
of G-CSF expression normalized to b2-microglobulin in Raw264.7 cells transfected with either LNA control (5nM) or LNA-antimiR (5nM) and
stimulated with 100ng/ml LPS for 6h. Values represent mean   SD (n=5). The P-values ( P<0.05;   P<0.01) are shown for two-sided Student’s
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cotransfected with 5nM pre-miR-155 in combination with either LNA control (5nM) or LNA-antimiR (5nM) before LPS stimulation for 6h.
Values represent mean   SD from one experiment performed in triplicate. The P-value (  P<0.01) is shown for two-sided Student’s t-test.
(C) Quantitative RT-PCR analysis of G-CSF expression normalized to GAPDH in splenocytes of mice treated with LNA-antimiR or LNA control
by three intravenous injections of 25mg/kg over three consecutive days. Spleen samples were dissected 2h after intraperitoneal injection of 0.5mg/kg
LPS. Values represent mean   SD (n=5). The P-values ( P<0.05;    P<0.001) are shown for two-sided Student’s t-test.
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ing of miR-155 by intravenously injected LNA-antimiR in
LPS-treated mice results in marked derepression of
the LAP and LIP isoforms of c/ebp Beta in mouse sple-
nocytes, indicating that miR-155 acts as an important neg-
ative regulator of c/ebp Beta in vivo during acute
inﬂammatory response.
A new discovery of this study is the ﬁnding that antag-
onism of miR-155 by LNA-antimiR leads to down-
regulation of the G-CSF mRNA in vitro and in vivo.
G-CSF is a master regulator of granulopoiesis produced
by activated macrophages during acute inﬂammatory
responses (27). Several studies have demonstrated that
G-CSF is involved in inﬂammation and that it aggravates
inﬂammatory diseases (28). G-CSF appears to play a
central role in arthritis, where administration of G-CSF
to mice has been shown to enhance collagen-induced
arthritis (29), while blocking of G-CSF, on the other
hand, markedly reduced disease manifestation in mice
(30). Furthermore, G-CSF-deﬁcient mice are protected
from acute and chronic arthritis (30). In patients with
active rheumatoid arthritis, G-CSF is elevated in the
serum and synovial ﬂuid and correlates with disease
severity (31). Hence, G-CSF is considered as a potential
therapeutic target for intervention of inﬂammatory joint
diseases, such as rheumatoid arthritis (28). However,
therapies that antagonize G-CSF may lead to neutrope-
nia. Thus, partial antagonism of endogenous G-CSF, as
described in this study for LNA-antimiR-mediated
G-CSF down-regulation, might provide a positive out-
come for arthritis patients without increased risk of
severe neutropenia. Indeed, our ﬁndings warrant further
investigations of the potential anti-inﬂammatory eﬀect of
miR-155 antagonism in relevant animal models of inﬂam-
matory disease, such as collagen-induced arthritis.
Previous studies have reported on impaired induction of
G-CSF in LPS-stimulated macrophages derived from mice
expressing only the dominant-negative LIP form of c/ebp
Beta (33). Interestingly, we ﬁnd that overexpression
of the LIP isoform of c/ebp Beta in mouse macrophages
results in down-regulation of the G-CSF transcript
(Supplementary Figure 2). Thus, it is possible that c/ebp
Beta, which is modulated by miR-155, acts in part by
ﬁne-tuning G-CSF expression levels, consistent with a
c/ebp Beta binding motif in the promoter of G-CSF
(15,32). However, since a single vertebrate miRNA may
target up to  100–200 mRNAs, it is highly likely that
functional antagonism of miR-155 in vivo results in
more complex downstream eﬀects that are associated
with miR-155-mediated gene regulatory networks.
Indeed, miR-155 was recently shown to regulate the
PI3K–AKT signaling pathway during LPS stimulation
of macrophages by targeting the inositol phosphatase
SHIP1 (34). Nevertheless, given the importance of
c/ebp Beta during macrophage activation and the role
of G-CSF in stimulating granulopoiesis in the bone
marrow, our data emphasize the potential of antagonizing
miR-155 for modulating activation of macrophages and
the number of circulating granulocytic cells with possible
implications for treatment of inﬂammatory diseases.
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